BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MB-001 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MB-001\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07374471-56@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:MB-001: Phase 1/2 readout est. (NCT07374471)
DESCRIPTION:MB-001\, phase 1/2\, Ulcerative Colitis.\nStudy: A Study of MB-
 001 in Moderately to Severely Active Ulcerative Colitis\nEstimated primary
  completion: July 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/mb-001#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07374471
URL:https://assetmemo.bio/drug/mb-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
